Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RMC-5127 · 1 trial · 10 indications
Number of patients with AEs as assessed by Common Terminology Criteria for Adverse Events CTCAE v5
Number of patients with changes from baseline in vital signs
Number of patients with changes from baseline in ECG test values
Number of patients with changes from baseline in clinical laboratory test values
Number of patients with dose limiting toxicities
| Arm | Type | Description |
|---|---|---|
| Arm A: RMC-5127 Monotherapy | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Arm B: RMC-5127 + Daraxonrasib Combination | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Arm C: RMC-5127 + Cetuximab Combination | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Name | Type | Description |
|---|---|---|
| RMC-5127 | DRUG | oral tablets |
| daraxonrasib | DRUG | oral tablets |
| cetuximab | DRUG | IV infusion |
Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy. * Received and progressed or been intolerant...
RMC-5127 is an investigational small molecule being studied for the treatment of non-small cell lung cancer (NSCLC). It is in Phase 1 clinical development for patients with advanced KRAS G12V-mutant solid tumors, including NSCLC, colorectal cancer, and pancreatic adenocarcinoma.
RMC-5127 targets RAS(ON) G12V, a specific mutant form of the RAS protein. By targeting this oncogenic variant, the drug aims to interfere with cancer cell signaling driven by the G12V mutation.
RMC-5127 is being developed by Revolution Medicines, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RVMD. The company is conducting clinical trials for this investigational oncology drug.
RMC-5127 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting patients with advanced KRAS G12V-mutant solid tumors.
RMC-5127 is being evaluated in a single Phase 1 clinical trial registered as NCT07349537, titled 'Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors.' The trial is recruiting in the United States and plans to enroll 574 participants aged 18 years and older.